<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534183</url>
  </required_header>
  <id_info>
    <org_study_id>CIPMETS001</org_study_id>
    <nct_id>NCT00534183</nct_id>
  </id_info>
  <brief_title>Metabolic Profile and Anthropometric Changes in Schizophrenia</brief_title>
  <acronym>MetS</acronym>
  <official_title>Metabolic Profile and Anthropometric Changes in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Psychiatry, Ranchi, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Psychiatry, Ranchi, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;No clinical differences will be found between the three antipsychotics under study -
      olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. &quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on
      development of metabolic syndrome in a drug na√Øve population suffering from first episode
      schizophrenia and compared it with a matched healthy control group. We also aimed to examine
      the prevalence of metabolic syndrome as defined by the two most widely accepted definitions,
      the ATP IIIA and the IDF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study of metabolic profile</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of obesity and diabetes</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2006</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>haloperidol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine in dose range of 10-20mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone 1-6mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Haloperidol 10-20mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-40 years

          -  Diagnosis of schizophrenia

          -  Drug naive on admission

        Exclusion Criteria:

          -  Other psychiatric co-morbidity

          -  History of severe physical illness

          -  Alcohol and substance abuse or dependence

          -  History of pre-existing diabetes or hypertension

          -  Family history of hypertension or diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahoo Saddichha, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Institute of Psychiatry</name>
      <address>
        <city>Ranchi</city>
        <zip>834009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>September 21, 2007</last_update_submitted>
  <last_update_submitted_qc>September 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2007</last_update_posted>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Obesity</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

